Merck & Co Inc
6MK
Company Profile
Business description
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. In cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 53% of the company's 2025 sales were generated from US human health (pharmaceuticals and vaccines).
Contact
126 East Lincoln Avenue
RahwayNJ07065
USAT: +1 908 740-4000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
75,000
Stocks News & Analysis
stocks
Cheap Dividend Aristocrat has Fair Value raised after earnings
Dividend forecasts raised after balance sheet regains strength.
stocks
Why great earnings haven't been good enough for AI hardware stocks
Stocks that had been posting triple-digit returns are sliding on earnings results.
stocks
Fair Value increased for Big 4 bank after earnings
Shares still overvalued, with analysts thinking the fundamentals no longer matter to the share price.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,306.00 | 26.80 | -0.29% |
| CAC 40 | 8,650.56 | 24.38 | -0.28% |
| DAX 40 | 26,299.74 | 31.33 | -0.12% |
| Dow JONES (US) | 53,839.99 | 69.72 | 0.13% |
| FTSE 100 | 10,772.67 | 60.48 | -0.56% |
| HKSE | 25,176.75 | 219.76 | -0.87% |
| NASDAQ | 26,803.03 | 214.54 | 0.81% |
| Nikkei 225 | 68,889.01 | 580.41 | 0.85% |
| NZX 50 Index | 13,817.11 | 8.19 | -0.06% |
| S&P 500 | 7,798.99 | 50.49 | 0.65% |
| S&P/ASX 200 | 9,108.60 | 26.50 | -0.29% |
| SSE Composite Index | 3,908.33 | 18.63 | -0.47% |